BUSINESS DAY TV: We will only approach parties once we are investigating them
Hardin Ratshisusu, deputy commissioner at the Competition Commission, speaks about investigating suspected collusion on the price of medication
Hardin Ratshisusu is deputy commissioner at the Competition Commission. BUSINESS DAY TV: The Competition Commission has announced that its going to look into suspected collusion in the pricing of cancer medication. This means that the commission will investigate companies like Aspen, Roche and Pfizer. Joining us for more is deputy commissioner at the Competition Commission Hardin Ratshisusu. Hardin, so what has alerted you to possible anticompetitive conduct within the pharmaceutical space? Or, is this merely being triggered by competition authorities over in the various European countries that of course put the spotlight on Aspen a few months ago? HARDIN RATSHISUSU: We have been doing a lot of background work on pharmaceuticals. We participate in a number of working groups globally, within Brics, we constantly engage with authorities elsewhere in scanning the environment to see what is going on around us. The US has had a lot of cases of pay-for-delay against pharmaceutical compani...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.